Palatin Technologies, Inc. PTN
Palatin Technologies, Inc. (Nasdaq: PTN) is an endocrine/women's health drug developer. Its lead program, MC4R selective long-acting peptide agonist, is in Pre-clinical for Rare obesity disorders (hypothalamic obesity, Prader-Willi syndrome, Bardet-Biedl syndrome).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Vyleesi (bremelanotide) | HSDD in premenopausal women | peptide | Approved |
| PL9643 | Dry eye disease | peptide | Phase 3 |
| Bremelanotide combination with tirzepatide | Obesity | peptide | Phase 2 |
| PL8177 | Ulcerative colitis | small molecule | Phase 2 |
| MC4R selective long-acting peptide agonist | Rare obesity disorders (HO, PWS, BBS) | peptide | Pre-clinical |
| MC4R selective oral small molecule agonist | Obesity and metabolic disorders | small molecule | Pre-clinical |
| Licensed MCR compounds (Boehringer Ingelheim) | Diabetic retinopathy and diabetic macular edema | peptide | Pre-clinical |
| Diabetic nephropathy program | Diabetic nephropathy | unclear | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical endocrine/women's health companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.